Boston Scientific Corporation (BSX) is gaining from strength across target markets. Strong worldwide demand for its GI and pulmonary treatment options, traction in Europe for its next-generation WATCHMAN FLX and contribution from accretive acquisitions are important drivers. However, unfavorable currency movements and stiff competition are a concern. In the past year, this Zacks Rank #2 (Buy) stock has gained 37.1% compared with a 5.5% fall of the industry and a 23.6% rise of the S&P 500. The renowned manuf ...